Inventor
MCINNES CAMPBELL
US18 patents
⚠️ This page may combine multiple inventors who share the name “MCINNES CAMPBELL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV SOUTH CAROLINA
11 patentsUS9376465B2Jun 28, 2016
Cyclin based inhibitors of CDK2 and CDK4
UNIV SOUTH CAROLINA5 citations83
US11014906B2May 25, 2021
Quinoline-based compounds and methods of inhibiting CDK8/19
UNIV SOUTH CAROLINA3 citations71
US10067131B2Sep 4, 2018
Fragment ligated inhibitors selective for the polo box domain of PLK1
UNIV SOUTH CAROLINA4 citations68
US11162083B2Nov 2, 2021
Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
UNIV SOUTH CAROLINA2 citations67
US9982015B2May 29, 2018
Cyclin based inhibitors of CDK2 and CDK4
UNIV SOUTH CAROLINA4 citations62
US12559733B2Feb 24, 2026
Optimization of type IV BRAF inhibitors for the treatment of melanoma
UNIV SOUTH CAROLINA0 citations57
US12415822B2Sep 16, 2025
Small molecule inhibitors selective for polo-like kinase protein
UNIV SOUTH CAROLINA0 citations54
US11597737B2Mar 7, 2023
Small molecule inhibitors selective for polo-like kinase proteins
UNIV SOUTH CAROLINA0 citations54
US12281080B2Apr 22, 2025
Quinoline-based compounds and methods of inhibiting CDK8/19
UNIV SOUTH CAROLINA0 citations50
US11712437B2Aug 1, 2023
Inhibitors of lysyl oxidases
UNIV SOUTH CAROLINA0 citations50
US11572369B2Feb 7, 2023
Bicyclic pyridine compositions and methods of using the same for cancer therapy
UNIV SOUTH CAROLINA0 citations48
CYCLACEL LTD
3 patentsMCINNES CAMPBELL
3 patentsUS8566072B2Oct 22, 2013
Cyclin based inhibitors of CDK2 and CDK4
MCINNES CAMPBELL11 citations82
US9328139B2May 3, 2016
Cyclin based inhibitors of CDK2 and CDK4
MCINNES CAMPBELL4 citations71
US9175357B2Nov 3, 2015
Fragment ligated inhibitors selective for the polo box domain of PLK1
MCINNES CAMPBELL4 citations66